Cullinan Therapeutics released clinical data from its ongoing Phase 1b/2a Genrix study of velinotamig in systemic lupus erythematosus. Results are being present

BWB News TV • 2026-11-08 15:36 UTC • By Billy Odell Tucker-Robinson

Cullinan Therapeutics released clinical data from its ongoing Phase 1b/2a Genrix study of velinotamig in systemic lupus erythematosus. Results are being presented at ACR26 as the company advances its broader autoimmune and oncology pipeline.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly